Slide 1: Q1'FY26 Earnings Call Supplemental Presentation
Q1’FY26 Earnings Call Supplemental Presentation November 5, 2025
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are not statements of historical fact are forward-looki
Slide 3: Vision and Mission
Vision and Mission To expand the curative power of radiation therapy to improve as many lives as possible. To think, act, and execute beyond expectations every day to deliver better, safer radiation therapy solutions and help patients get back to living their lives, faster. Proprietary and Confident
Slide 4: Introduced Accuray Stellar Solution at ASTRO
Introduced Accuray Stellar * Solution at ASTRO Accuray Stellar is a configuration of the Radixact® Treatment Delivery System Tailored Efficient Comprehensive *Accuray Stellar is currently available for the US market. Accuray Stellar maybe subject to international regulatory approval or licensing pro
Slide 5: Q1'FY26 Financials
Q1’FY26 Financials Highlights KEY FINANCIAL METRICS $M Q1 Y/Y ▪ Continued strong service revenue growth; Q1 service revenue growth rate higher than Revenues $93.9 (7%) install base growth for the same period Product $37.1 (23%) ▪ Adjusting for China margin deferral of $1.1 million, Q1 gross margins
Slide 6: China Deferred Margin Impact
China Deferred Margin Impact FY25 FY26 ▪ Due to JV accounting rules, 49% $k YTD Q1 of total margin is deferred upon Net China Margin Impact (Deferral) / Release (7,666) (1,081) shipment to the JV and margin is released when the JV ships the Total Gross Margin % Reported 32.1% 28.3% system to its cus
Slide 7: Maintaining FY26 Guidance
Maintaining FY26 Guidance $ in millions FY26 % = YoY Growth Guidance Range $471M - $485M Revenue +3% - +6% $31M - $35M Adjusted EBITDA1 +10% - +25% 1 Adjusted EBITDA is a non-GAAP measure. Please see Slide 11 for a reconciliation of Adjusted EBITDA to the most directly comparable GAAP measure. Propr
Slide 8: Thank you
Thank you Proprietary and Confidential Property of Accuray 8
Slide 9: GAAP to Adjusted EBITDA Q1 FY'26 and Q1 FY'25
GAAP to Adjusted EBITDA Q1 FY’26 and Q1 FY’25 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Three Months Ended September 30, $K 2025 2024 GAAP net loss $ (21,678) $ (3,954) Depreciation and a
Slide 10: GAAP to Adjusted EBITDA FY2025
GAAP to Adjusted EBITDA FY2025 Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Twelve Months Ended June 30, $K 2025 GAAP net loss $ (1,591) Depreciation and amortization 6,150 Stock-based compe
Slide 11: GAAP to Adjusted EBITDA FY'26 – Forward Looking Guidance
GAAP to Adjusted EBITDA FY’26 – Forward Looking Guidance Reconciliation of Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation (Adjusted EBITDA) Twelve Months Ended June 30, 2026 $K From To GAAP net loss $ (30,000) $ (27,500) Depreci
Slide 12: Gross Margin to Gross Margin Excluding China Margin Impact
Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact Twelve Months Ended June 30, $K 2025 Total Net Revenue $ 458,505 Total Cost of Revenue (311,538) Gross Profit 146,967 China Margin Deferral (7,666) Gross Profit exc
Slide 13: Gross Margin to Gross Margin Excluding China Margin Impact
Gross Margin to Gross Margin Excluding China Margin Impact Reconciliation of Gross margin to Gross margin excluding China Margin Impact Three Months Ended September 30, $K 2025 Total Net Revenue $ 93,942 Total Cost of Revenue (67,394) Gross Profit 26,548 China Margin Deferral (1,081) Gross Profit ex